David Willner

2.3k total citations
28 papers, 1.8k citations indexed

About

David Willner is a scholar working on Oncology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, David Willner has authored 28 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Organic Chemistry and 8 papers in Molecular Biology. Recurrent topics in David Willner's work include Peptidase Inhibition and Analysis (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and HER2/EGFR in Cancer Research (4 papers). David Willner is often cited by papers focused on Peptidase Inhibition and Analysis (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and HER2/EGFR in Cancer Research (4 papers). David Willner collaborates with scholars based in United States, Germany and Switzerland. David Willner's co-authors include Pamela A. Trail, Shirley J. Lasch, Raymond A. Firestone, Sandra J. Hofstead, Jay O. Knipe, Ingegerd Hellström, Gene M. Dubowchik, K E Hellström, Arris J. Henderson and Gary R. Braslawsky and has published in prestigious journals such as Science, Journal of the American Chemical Society and Journal of Controlled Release.

In The Last Decade

David Willner

28 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Willner United States 17 799 762 757 322 270 28 1.8k
Sandra J. Hofstead United States 14 659 0.8× 636 0.8× 728 1.0× 417 1.3× 181 0.7× 14 1.6k
Shirley J. Lasch United States 11 722 0.9× 680 0.9× 600 0.8× 151 0.5× 211 0.8× 11 1.4k
Gary R. Braslawsky United States 20 496 0.6× 372 0.5× 570 0.8× 142 0.4× 216 0.8× 34 1.2k
Rajeeva Singh United States 22 801 1.0× 940 1.2× 872 1.2× 247 0.8× 108 0.4× 43 2.0k
Joseph M. Backer United States 31 687 0.9× 320 0.4× 1.5k 2.0× 150 0.5× 283 1.0× 97 2.9k
Kathleen R. Whiteman United States 24 787 1.0× 1.0k 1.3× 1.1k 1.4× 333 1.0× 769 2.8× 45 2.5k
Pavla Rejmanová Czechia 18 213 0.3× 337 0.4× 732 1.0× 406 1.3× 748 2.8× 23 1.6k
Ingrid Dijkgraaf Netherlands 24 1.0k 1.3× 738 1.0× 818 1.1× 230 0.7× 137 0.5× 57 2.2k
Roger F. Zabinski United States 11 1.2k 1.5× 1.4k 1.8× 808 1.1× 206 0.6× 105 0.4× 11 2.1k
Brian E. Toki United States 14 1.4k 1.8× 1.6k 2.1× 1.1k 1.5× 549 1.7× 105 0.4× 15 2.9k

Countries citing papers authored by David Willner

Since Specialization
Citations

This map shows the geographic impact of David Willner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Willner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Willner more than expected).

Fields of papers citing papers by David Willner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Willner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Willner. The network helps show where David Willner may publish in the future.

Co-authorship network of co-authors of David Willner

This figure shows the co-authorship network connecting the top 25 collaborators of David Willner. A scholar is included among the top collaborators of David Willner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Willner. David Willner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dubowchik, Gene M., Harold Mastalerz, Michael Walker, et al.. (2002). Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages. Bioorganic & Medicinal Chemistry Letters. 12(11). 1529–1532. 30 indexed citations
2.
Trail, Pamela A., David Willner, A. Bianchi, et al.. (1999). Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.. PubMed. 5(11). 3632–8. 32 indexed citations
3.
King, Dalton, David Willner, Raymond A. Firestone, et al.. (1999). Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Linkers:  A Novel Method for Increasing the Potency of Doxorubicin Immunoconjugates. Bioconjugate Chemistry. 10(2). 279–288. 60 indexed citations
4.
Trail, Pamela A., David Willner, Jay O. Knipe, et al.. (1997). Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.. PubMed. 57(1). 100–5. 45 indexed citations
5.
Firestone, Raymond A., David Willner, Sandra J. Hofstead, et al.. (1996). Synthesis and antitumor activity of the immunoconjugate BR96-Dox. Journal of Controlled Release. 39(2-3). 251–259. 27 indexed citations
6.
Trail, Pamela A., David Willner, & Karl Erik Hellström. (1995). Site‐directed delivery of anthracyclines for treatment of cancer. Drug Development Research. 34(2). 196–209. 13 indexed citations
7.
Trail, Pamela A., David Willner, Shirley J. Lasch, et al.. (1993). Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates. Science. 261(5118). 212–215. 414 indexed citations
8.
Willner, David, Pamela A. Trail, Sandra J. Hofstead, et al.. (1993). (6-Maleimidocaproyl)hydrazone of doxorubicin. A new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjugate Chemistry. 4(6). 521–527. 183 indexed citations
9.
Willner, David, et al.. (1992). Determination of immunoreactivity of doxorubicin antibody immunoconjugates by a Ley competitive RIA. Bioconjugate Chemistry. 3(6). 549–553. 3 indexed citations
10.
Trail, Pamela A., David Willner, Shirley J. Lasch, et al.. (1992). Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.. PubMed. 52(20). 5693–700. 50 indexed citations
11.
Kaneko, Takushi, David Willner, Ivo Monković, et al.. (1991). New hydrazone derivatives of Adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity. Bioconjugate Chemistry. 2(3). 133–141. 138 indexed citations
12.
Monković, Ivo, et al.. (1988). Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis. Journal of Medicinal Chemistry. 31(8). 1548–1558. 24 indexed citations
13.
Willner, David, et al.. (1973). AN IMPROVED PREPARATION OF DESAGETYLGEPHALOGLYGIN. The Journal of Antibiotics. 26(3). 179–180. 6 indexed citations
14.
Willner, David, et al.. (1972). 7-(α-AMINOPHENYLACETAMIDO)-3-AZIDOMETHYL-3-CEPHEM-4-CARBOXYLIG ACID. The Journal of Antibiotics. 25(1). 64–67. 3 indexed citations
15.
Lavie, David, et al.. (1964). Constituents of Citrullus colocynthis (L.) Schrad.. Phytochemistry. 3(1). 51–56. 21 indexed citations
16.
Berson, Jerome A. & David Willner. (1962). An Optically Inactive Intermediate in the Multiple Rearrangement of exo-2-Aminomethylnorbornane. Journal of the American Chemical Society. 84(4). 675–676. 11 indexed citations
17.
Berson, Jerome A., et al.. (1961). The Absolute Configurations of Some Simple Norbornane Derivatives. A Test of the “Conformational Asymmetry” Model1a. Journal of the American Chemical Society. 83(19). 3986–3997. 87 indexed citations
18.
Lavie, David & David Willner. (1960). The Constituents of Ecballium elaterium L. XI. Proposed Structures for α-Elaterin and its Degradation Products1,2. Journal of the American Chemical Society. 82(7). 1668–1673. 10 indexed citations
19.
Lavie, David, et al.. (1959). New compounds from plants with anti-tumor activity.. PubMed. 15(Suppl 1). 177–81. 3 indexed citations
20.
Lavie, David & David Willner. (1958). The Constituents of Ecballium elaterium L. III. Elatericin A and B1,2. Journal of the American Chemical Society. 80(3). 710–714. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra J. Hofstead Breakdown of academic impact, for papers by Shirley J. Lasch Breakdown of academic impact, for papers by Gary R. Braslawsky Breakdown of academic impact, for papers by Rajeeva Singh Breakdown of academic impact, for papers by Joseph M. Backer Breakdown of academic impact, for papers by Kathleen R. Whiteman Breakdown of academic impact, for papers by Pavla Rejmanová Breakdown of academic impact, for papers by Ingrid Dijkgraaf Breakdown of academic impact, for papers by Roger F. Zabinski Breakdown of academic impact, for papers by Brian E. Toki
Rankless by CCL
2026